Based on the CT findings of a 1.2 cm circumferential wall thickening of the distal stomach extending into the duodenum and possibly invading the left liver lobe, with no enlarged regional lymph nodes and no definite distant metastasis, what is the clinical TNM stage and overall stage group for this gastric adenocarcinoma?

Clinical TNM Staging of Gastric Adenocarcinoma

Based on the CT findings, this gastric adenocarcinoma is most consistent with clinical stage cT4aN0M0 (Stage IIB), though definitive staging requires staging laparoscopy to exclude occult peritoneal metastases before proceeding with curative-intent therapy. 1

Primary Tumor (T) Stage Assessment

The imaging demonstrates cT4a disease based on the following features: 1

• Circumferential wall thickening of 1.2 cm involving the antrum to pyloric canal with mucosal enhancement 1
• Critical finding: The superior portion of the thickened pyloric canal is "difficult to separate from the inferior edge of segment III of the left liver lobe" 1
• This suggests possible invasion of adjacent structures (liver), which would classify as T4a if limited to serosal penetration with contact, or T4b if there is definitive invasion into the liver parenchyma 2, 1

Important caveat: The 1.2 cm wall thickness alone can mimic malignancy—benign conditions like H. pylori gastritis can produce similar circumferential antral thickening of 1.5-2.0 cm. 3 However, given the clinical context of confirmed adenocarcinoma, this represents tumor infiltration rather than inflammation.

The extension into the first part of the duodenum represents intramural extension, which is classified by the depth of invasion at the primary gastric site, not as a separate T4 criterion. 2

Regional Lymph Node (N) Stage Assessment

cN0 (no regional lymph node metastasis) based on: 1

• CT report explicitly states "No enlarged mesenteric, retroperitoneal or pelvic lymph nodes" 1
• For gastric cancer staging, lymph nodes are considered abnormal when short-axis diameter ≥1.0 cm, or when demonstrating irregular morphology, unclear boundaries, or heterogeneous enhancement 2, 1
• The absence of enlarged regional lymph nodes (perigastric, celiac axis, hepatic artery, splenic nodes) supports cN0 classification 1, 4

Critical pitfall: Clinical N0 staging has significant limitations—approximately 20-25% of clinically N0 patients harbor occult lymph node metastases detectable only on pathological examination. 4 This underscores why adequate lymph node harvest (minimum 16 nodes, optimally ≥25 nodes) is mandatory for accurate pathological staging. 2

Distant Metastasis (M) Stage Assessment

cM0 (no definitive distant metastasis), though several findings require clarification: 1

• Liver lesion: 0.5 cm non-enhancing hypodense focus in segment 8 is too small and non-specific to definitively diagnose metastasis on CT alone 1
• Kidney lesions: Multiple bilateral renal lesions (simple cysts, complex cyst with calcification, fat-containing lesion consistent with angiomyolipoma) represent benign findings unrelated to gastric cancer staging 1
• Appendiceal findings: Enlarged fluid-filled appendix (1 cm diameter) with wall thickening and minimal fat stranding suggests acute appendicitis, not metastatic disease 1
• Gallbladder: Lamellated calcific density (1.2 cm) represents a gallstone, not a metastatic focus 1

No ascites or peritoneal nodularity is documented, which argues against peritoneal carcinomatosis. 1

Overall Stage Group

Provisional clinical stage: IIB (cT4aN0M0) 1

However, this staging is incomplete without mandatory staging laparoscopy, which is essential because: 2, 1

• Laparoscopy with peritoneal washings detects occult peritoneal metastases in 20-30% of patients with T3/T4 gastric cancer who appear resectable on CT 1, 4
• Detection of peritoneal disease or positive cytology upstages to Stage IV (M1), fundamentally changing management from curative surgery to palliative systemic therapy 1
• This is particularly critical for antral tumors with possible serosal involvement 1

Mandatory Next Steps Before Treatment Planning

Staging laparoscopy with peritoneal washings must be performed before proceeding with curative-intent surgery to exclude occult M1 disease. 2, 1

Endoscopic ultrasound (EUS) should be obtained to: 2, 1

• Better define the depth of invasion (distinguish T4a from T4b)
• Clarify the relationship between the tumor and the liver
• Assess for regional lymph nodes not adequately visualized on CT

Multidisciplinary tumor board review is mandatory before initiating therapy, including surgical oncology, medical oncology, radiation oncology, gastroenterology, radiology, and pathology. 2, 1

HER2 testing should be performed on the original biopsy specimen if metastatic disease is confirmed, as this directly impacts eligibility for trastuzumab-based therapy. 1

Common Staging Pitfalls to Avoid

• Proceeding to surgery without laparoscopy: This misses 20-30% of patients with peritoneal disease, subjecting them to non-curative surgery with significant morbidity. 1, 4
• Over-interpreting small liver lesions: The 0.5 cm liver lesion is below the threshold for confident characterization and likely represents a benign cyst or hemangioma. 1
• Relying solely on CT for T-staging: CT has limited accuracy for distinguishing T3 from T4a disease; EUS provides superior depth-of-invasion assessment. 2, 1
• Accepting inadequate lymph node assessment: Ensure surgical planning includes D2 lymphadenectomy with harvest of ≥16 nodes (optimally ≥25) for accurate pathological staging. 2, 4